These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 27627093)

  • 1. [A near future of treatment of dyslipidemia in type 2 diabetics].
    Vrablík M
    Vnitr Lek; 2016; 62(7-8):652-60. PubMed ID: 27627093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future perspectives of the pharmacological management of diabetic dyslipidemia.
    Patti AM; Giglio RV; Papanas N; Rizzo M; Rizvi AA
    Expert Rev Clin Pharmacol; 2019 Feb; 12(2):129-143. PubMed ID: 30644763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of ApoCIII to Diabetic Dyslipidemia and Treatment With Volanesorsen.
    Zhang J; Rocha NA; McCullough PA
    Rev Cardiovasc Med; 2018 Mar; 19(1):13-19. PubMed ID: 31032598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Cardiovasc Diabetol; 2006 Sep; 5():20. PubMed ID: 17002798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia].
    Im M; Kim M; Lee JK; Chang YH; Lee DY; Hong SI; Lee YY; Hong YJ
    Korean J Lab Med; 2010 Feb; 30(1):17-9. PubMed ID: 20197717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes.
    Campbell J; Mohiuddin SM
    Drugs Today (Barc); 2010 Oct; 46(10):757-64. PubMed ID: 21076712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New frontiers in the treatment of diabetic dyslipidemia.
    Wang SY; Hsieh MC; Tu ST; Chuang CS
    Rev Diabet Stud; 2013; 10(2-3):204-12. PubMed ID: 24380093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins.
    Anabtawi A; Moriarty PM; Miles JM
    Curr Cardiol Rep; 2017 Jul; 19(7):62. PubMed ID: 28528456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Lipid Abnormalities in Patients with Diabetes.
    Sillars A; Sattar N
    Curr Cardiol Rep; 2019 Nov; 21(11):147. PubMed ID: 31758270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological management of diabetic dyslipidemia.
    Filippatos TD; Florentin M; Georgoula M; Elisaf MS
    Expert Rev Clin Pharmacol; 2017 Feb; 10(2):187-200. PubMed ID: 27868450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dyslipemia in diabetics treated with statins. Results of the DYSIS study in Spian].
    Millán J; Alegría E; Guijarro C; Lozano JV; Vitale GC; González-Timón B; González-Juanatey JR
    Med Clin (Barc); 2013 Nov; 141(10):430-6. PubMed ID: 23246165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia.
    Ghani RA; Bin Yaakob I; Wahab NA; Zainudin S; Mustafa N; Sukor N; Wan Mohamud WN; Kadir KA; Kamaruddin NA
    J Clin Lipidol; 2013; 7(5):446-53. PubMed ID: 24079286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expediency of the use of fibrates for primary and secondary prevention of cardiovascular complications.].
    Mamedov MN
    Kardiologiia; 2006; 46(12):39-47. PubMed ID: 17310961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dyslipidemia in type 2 diabetes mellitus.
    Mooradian AD
    Nat Clin Pract Endocrinol Metab; 2009 Mar; 5(3):150-9. PubMed ID: 19229235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
    Costet P; Hoffmann MM; Cariou B; Guyomarc'h Delasalle B; Konrad T; Winkler K
    Atherosclerosis; 2010 Sep; 212(1):246-51. PubMed ID: 20619837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
    Ascaso J; Gonzalez Santos P; Hernandez Mijares A; Mangas Rojas A; Masana L; Millan J; Pallardo LF; Pedro-Botet J; Perez Jimenez F; Pintó X; Plaza I; Rubiés J; Zúñiga M
    Am J Cardiovasc Drugs; 2007; 7(1):39-58. PubMed ID: 17355165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.